Evogene (NASDAQ:EVGN) Given a $3.50 Price Target by Lake Street Capital Analysts

Lake Street Capital set a $3.50 price objective on Evogene (NASDAQ:EVGN) in a research note published on Thursday, MarketBeat reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also issued reports on the stock. Wall Street Zen assumed coverage on shares of Evogene in a report on Wednesday. They set a “sell” rating for the company. Alliance Global Partners restated a “buy” rating on shares of Evogene in a report on Friday, March 7th.

Evogene Stock Performance

Evogene stock opened at $1.19 on Thursday. Evogene has a 52-week low of $0.95 and a 52-week high of $9.00. The firm has a 50 day moving average price of $1.18 and a two-hundred day moving average price of $1.44. The firm has a market cap of $6.36 million, a price-to-earnings ratio of -0.27 and a beta of 1.55.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.12. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The firm had revenue of $2.44 million during the quarter, compared to analyst estimates of $4.42 million.

Institutional Trading of Evogene

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in shares of Evogene in the 4th quarter valued at $30,000. Jane Street Group LLC acquired a new stake in Evogene in the 4th quarter valued at $40,000. Finally, Armistice Capital LLC grew its position in Evogene by 5.9% in the 1st quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 17,743 shares during the period. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.